JPMorgan Insurance Trust U.S. Equity Portfolio Schedule of Portfolio Investments as of March 31, 2022 (Unaudited)

THE "UNAUDITED MUTUAL FUNDS HOLDINGS" LIST ("the List") IS TO BE USED FOR REPORTING PURPOSES ONLY. IT IS NOT TO BE REPRODUCED FOR USE AS ADVERTISING OR SALES LITERATURE WITH THE GENERAL PUBLIC. The list is submitted for the general information of the shareholders of the Fund. It is not authorized for distribution to prospective investors in the Fund unless preceded or accompanied by a prospectus. The list has been created from the books and records of the Fund. Holdings are available 60 days after the fund's fiscal quarter, using a trade date accounting convention, by contacting the appropriate service center. The list is subject to change without notice. The list is for informational purposes only and is not intended as an offer or solicitation with respect to the purchase or sale of any security.

JPMorgan Asset Management is the marketing name for the asset management business of J.P. Morgan Chase & Co.

JPMorgan Distribution Services, Inc., member FINRA.

© J.P. Morgan Chase & Co., 2022.

SCHEDULE OF PORTFOLIO INVESTMENTS

AS OF MARCH 31, 2022 (Unaudited)

COMON STOCK 97.5% Aerospace & Defense 1.8% Howmet Aerospace, Inc. \$ \$ \$ \$ \$ \$ \$ \$ \$	Investments	Shares (000)	Value (\$000)
Howmet Aerospace, Inc. Northrop Grumman Corp.	COMMON STOCKS — 97.5%		
Northrop Grumman Corp. 4 1.32 Raytheon Echnologies Corp. 4 431 Textron, Inc. 3 245 Air Freight & Logistics — 0.4% ————————————————————————————————————			
Rayheon Technologies Corp. 4 431 3 245 24676 24676 24676 3 24576 3 24576 3 24576 3 24576 3 24576 3 24576 3 24576 3 24576 3 24576 3 25576 3 3 24576 3 24576 3 3 24576 3 245			
Textron, Inc. 3 245 Air Freight & Logistics — 0.4% 1 2.676 FedEx Corp. 1 203 United Parcel Service, Inc., Class B 1 318 Automobiles — 1.7%			
Air Freight & Logistics — 0.4% 2,676 FedEx Corp. 1 203 United Parcel Service, Inc., Class B 1 318 Automobiles — 1.7% 3 137 General Motors Co.* 3 1 61 Rivian Automotive, Inc., Class A*(a) 1 61 1 61 Tesla, Inc. * 2 2,333 1 7 Banks — 4.9% 9 375 5 1 61 1 28 4,255 1 2,531 1 2,531 1 2,531 1 6 1 2,531 1 6 1 2,531 1 1 2,42 2,535 1 1 2,42 2,535 1 1 2,42 2,536 US Bancorp 9 3,75 4 2,256 US Bancorp 42 2,256 US Bancorp 2,266 US Bancorp 2,226 4 2,256 US Bancorp 2,226 4 2,256 US Bancorp 2,226 4 2,256 US Ba			
FedEx Corp. 1 203	Textron, Inc.	3	245
FedEx Corp.			2,676
United Parcel Service, Inc., Class B 3 18 Automobiles — 1.7% 3 137 General Motors Co.* 3 16 Rivian Automotive, Inc., Class A*(a) 1 61 Tesla, Inc.* 2 2,333 Banks — 4.9% 2 Bank of America Corp. 9 375 Fifth Third Bancorp 8 345 SVB Financial Group* 1 284 Truist Financial Corp. 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Tocas-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp.* 3 231 Biotechnology — 4.7% 28 1,709 AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 163 Biomain Pharmaceutical, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 83 Capital Markets — 3.5%	Air Freight & Logistics — 0.4%		
Automobiles - 1.7% 3 137 Rivian Automotive, Inc., Class A*(a) 1 61 61 75 61 75 61 75 61 75 75 75 75 75 75 75 7	FedEx Corp.	1	203
Automobiles — 1.7% General Motors Co. * 3 137 Rivian Automotive, Inc., Class A * (a) 1 61 Tesla, Inc. * 2 2,333 Banks — 4.9%	United Parcel Service, Inc., Class B	1	318
General Motors Co. * 3 137 Rivian Automotive, Inc., Class A * (a) 1 61 Tesla, Inc. * 2 2,333 Banks — 4.9%			521
General Motors Co. * 3 137 Rivian Automotive, Inc., Class A * (a) 1 61 Tesla, Inc. * 2 2,333 Banks — 4.9%	Automobiles — 1.7%		
Rivian Automotive, Inc., Class A* (a) 1 61 Tesla, Inc.* 2 2,333 Banks — 4.9% 8 3.75 Bank of America Corp. 8 3.45 SVB Financial Group * 1 2.84 Trust Financial Corp. 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Reverages—1.5% Coca-Cola Co., (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology—4.7% 2 4,047 Biogen, Inc. * 1 176 Biodynin Pharmaceutical, Inc. * 2 1,48 Regeneron Pharmaceutical, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 1 83 Sarepta Therapeutics, Inc. * 1 2,54 Tranc Technologies plc 1 1,481 Capital Markets—3.5% 5 4,95 Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4		3	137
Tesla, Inc. * 2 2,333 Banks — 4.9% 375 Bank of America Corp. 9 375 Fifth Third Bancorp 8 345 SVB Financial Group * 1 284 Truist Financial Corp. 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Everages — 1.5% 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 2 4,047 Biogen, Inc. * 2 4,047 Biogen, Inc. * 1 1 10 AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 1 16 Biogen, Inc. * 1 1 16 Biogen, Inc. * 1 1 16 Biodering Pharmaceutical, Inc. * 1 8 2 1 8			
3,53 Banks — 4.9% Bank of America Corp. 9 3.75 Fifth Third Bancorp 8 3.45 SVB Financial Group* 1 2.84 Truist Financial Corp. 42 2.356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2.269 Beverages — 1.5% 2 7,226 Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 23 Monster Beverage Corp.* 3 231 Biotechnology — 4.7% 3 231 Biotechnology — 4.7% 2 4,047 Biogen, Inc. * 1 16 Biomarin Pharmaceutical, Inc. * 1 16 Regeneron Pharmaceuticals, Inc. * 1 2 Vertex Pharmaceuticals, Inc. * 1 2 Vertex Pharmaceuticals, Inc. * 1 2 Trane Technologies plc 1 1,81 Capital Markets — 3.5% 4 3 Ameriprise Fi		2	
Banks — 4.9% 9 375 Bank of America Corp. 9 375 Fifth Third Bancorp 8 345 SVB Financial Group * 1 284 Truist Financial Corp. 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Beverages — 1.5% Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 1.76 BioMarin Pharmaceutical, Inc. * 1 1.03 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 1 8.3 Vertex Pharmaceuticals, Inc. * 1 8.3 Capital Markets — 3.5% 3 1.451	·		
Bank of America Corp. 9 375 Fifth Third Bancorp 8 345 SVB Financial Group* 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Beverages — 1.5% 7,226 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 1.03 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceutical, Inc. * 1 8.3 Vertex Pharmaceuticals, Inc. * 1 8.3 Vertex Pharmaceuticals, Inc. * 1 8.3 Vertex Pharmaceuticals, Inc. * 1 8.5 Trane Technologies plc 1 1,481 Capital Markets — 3.5% 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 9 1,620 S&P Global, Inc. 5 4,50 S&P Global, Inc. 5 4,50	Ranks 4 00%		
Fifth Third Bancorp 8 345 SVB Financial Group* 1 284 Truist Financial Corp. 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Beverages — 1.5% Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 103 Neurocrine Biosciences, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 25 Building Products — 1.0% 1 254 Trane Technologies plc 1 4 319 Charles Schwab Corp. (The) 4 319 Morgan Stanley 3 1,3		Q	375
SVB Financial Group* 1 2.84 Truist Financial Corp. 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Beverages — 1.5% Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Building Products — 1.0% 1 4,81 Trane Technologies plc 1 1,481 Charles Schwab Corp. (The) 4 319 Morgan Stanley 9 1,620 S&P Global, Inc. 3 1,310 State Street Corp. 5 4,51			
Truist Financial Corp. 42 2,356 US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Reverages — 1.5% Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Ameriprise Financial, Inc. * 5 1,481 Capital Markets — 3.5% 3 1,481 Charles Schwab Corp. (The) 4 319 Morgan Stanley 1 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450			
US Bancorp 30 1,597 Wells Fargo & Co. 47 2,269 Beverages — 1.5% Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 2,31 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 254 Evertex Pharmaceuticals, Inc. * 1 254 Wertex Pharmaceuticals, Inc. * 1 254 Building Products — 1.0% 1 254 Trane Technologies plc 5 1,451 Capital Markets — 3.5% 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 9 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1%			
Wells Fargo & Co. 47 2,269 Beverages — 1.5% Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology — 4.7% 25 4,047 AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 83 Building Products — 1.0% 1 254 Trane Technologies plc 1 1,481 Capital Markets — 3.5% 3 1,451 Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 1 1,620 State Street Corp. 5 450 Chemicals — 2.1% 5			
Beverages — 1.5% 7,226 Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 2,173 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Building Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 9 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 5 450 DuPont de Nemours, Inc. 1 71			
Beverages — 1.5% 1 28 1,709 Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 2,173 Biotechnology — 4.7% Abb Vie, Inc. 25 4,047 Biogen, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Building Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,451 Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 <	Wells Large & Co.	.,	
Coca-Cola Co. (The) 28 1,709 Constellation Brands, Inc., Class A 1 233 Monster Beverage Corp. * 3 231 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Building Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 5,156 DuPont de Nemours, Inc. 1 71	Dovomoros 1 50/		7,220
Constellation Brands, Inc., Class A Monster Beverage Corp. * 3 231 Eliotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Euilding Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,51 Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 1 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 5 450 DuPont de Nemours, Inc. 1 71		28	1 700
Monster Beverage Corp. * 3 231 Biotechnology — 4.7% AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Building Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 5 1,451 Charles Schwab Corp. (The) 3 1,316 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 1 71 DuPont de Nemours, Inc. 1 71			
Biotechnology - 4.7%			
Biotechnology — 4.7% Abb Vie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Engliding Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 5 1 DuPont de Nemours, Inc. 1 71	Molister Beverage Corp.	3	
AbbVie, Inc. 25 4,047 Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 6,950 Building Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 1 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 1 71 DuPont de Nemours, Inc. 1 71	D1 4 1 1 4 70/		2,1/3
Biogen, Inc. * 1 176 BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 Building Products — 1.0% 1 254 Trane Technologies plc 10 1,481 Capital Markets — 3.5% 3 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 1 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 5 450 DuPont de Nemours, Inc. 1 71	· ·	25	4.047
BioMarin Pharmaceutical, Inc. * 1 103 Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 6,950 Building Products — 1.0% - - Trane Technologies plc 10 1,481 Capital Markets — 3.5% - - Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% - 5 DuPont de Nemours, Inc. 1 71			
Neurocrine Biosciences, Inc. * 2 148 Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 6,950 Building Products — 1.0% - - Trane Technologies plc 10 1,481 Capital Markets — 3.5% - - Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% - 5 1 DuPont de Nemours, Inc. 1 71			
Regeneron Pharmaceuticals, Inc. * 3 2,139 Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 6,950 Building Products — 1.0% Trane Technologies plc 10 1,481 Capital Markets — 3.5% Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
Sarepta Therapeutics, Inc. * 1 83 Vertex Pharmaceuticals, Inc. * 1 254 6,950 Building Products — 1.0% Trane Technologies plc 10 1,481 Capital Markets — 3.5% Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% 5 1 DuPont de Nemours, Inc. 1 71			
Vertex Pharmaceuticals, Inc. * 1 254 6,950 Building Products — 1.0% Trane Technologies plc 10 1,481 Capital Markets — 3.5% Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71		_	
6,950 Building Products — 1.0% Trane Technologies plc 10 1,481 Capital Markets — 3.5% Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
Building Products — 1.0% Trane Technologies plc 10 1,481 Capital Markets — 3.5% Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71	vertex Filarmaceuticals, inc.	1	
Trane Technologies plc 10 1,481 Capital Markets — 3.5% Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			6,950
Capital Markets — 3.5% Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
Ameriprise Financial, Inc. 5 1,451 Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71		10	1,481
Charles Schwab Corp. (The) 4 319 Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
Morgan Stanley 19 1,620 S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
S&P Global, Inc. 3 1,316 State Street Corp. 5 450 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
State Street Corp. 5 450 5,156 5,156 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
5,156 Chemicals — 2.1% DuPont de Nemours, Inc. 1 71			
Chemicals — 2.1% DuPont de Nemours, Inc.	State Street Corp.	5	
DuPont de Nemours, Inc. 1 71			5,156
Eastman Chemical Co. 10 1,151		•	
	Eastman Chemical Co.	10	1,151

Linde plc (United Kingdom) PPG Industries, Inc. Construction Materials — 0.5% Martin Marietta Materials, Inc. Vulcan Materials Co. Consumer Finance — 0.3% American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc. Xcel Energy, Inc.	1 10 — (b) 3	474 1,375 3,071 168 577 745
Construction Materials — 0.5% Martin Marietta Materials, Inc. Vulcan Materials Co. Consumer Finance — 0.3% American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.	— (b) 3	3,071 168 577 745
Martin Marietta Materials, Inc. Vulcan Materials Co. Consumer Finance — 0.3% American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.	2	168 577 745
Martin Marietta Materials, Inc. Vulcan Materials Co. Consumer Finance — 0.3% American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.	2	577 745 430
Vulcan Materials Co. Consumer Finance — 0.3% American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.	2	577 745 430
Consumer Finance — 0.3% American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.	2	745 430
American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.		430
American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.		
American Express Co. Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.		
Diversified Financial Services — 0.1% Voya Financial, Inc. Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.	2	-10
Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.	2	
Electric Utilities — 3.5% Exelon Corp. NextEra Energy, Inc.		124
Exelon Corp. NextEra Energy, Inc.		
NextEra Energy, Inc.	7	329
	43	3,61
	16	1,170
		5,112
Electrical Equipment — 2.4%		
AMETEK, Inc.	1	13
Eaton Corp. plc	23	3,429
ation Corp. pic	23	3,560
Enguery Equipment 9 Couries 0 40/		3,30
Energy Equipment & Services — 0.4%	16	579
Baker Hughes Co.	10	578
Entertainment — 0.1%	~	1.4
Endeavor Group Holdings, Inc., Class A *	5	14
Equity Real Estate Investment Trusts (REITs) — 2.9%		
Host Hotels & Resorts, Inc.	11	20
Prologis, Inc.	22	3,63
Sun Communities, Inc.	2	33
Ventas, Inc.	2	14:
		4,31
Food Products — 0.2%		
Mondelez International, Inc., Class A	4	26
Health Care Equipment & Supplies — 2.7%		
Boston Scientific Corp. *	46	2,05
ntuitive Surgical, Inc. *	5	1,64
Zimmer Biomet Holdings, Inc.	2	29
		3,99
Health Care Providers & Services — 2.3%		
Centene Corp. *	26	2,19
JnitedHealth Group, Inc.	2	1,12
		3,31
Hotels, Restaurants & Leisure — 3.4%		
Booking Holdings, Inc. *	— (b)	16
Chipotle Mexican Grill, Inc. *	— (b)	22
Expedia Group, Inc. *	1	15
Hilton Worldwide Holdings, Inc. *	1	19
Marriott International, Inc., Class A *	8	1,41
McDonald's Corp.	10	2,57
Yum! Brands, Inc.	2	28
		5,00
Household Durables — 0.1%		
Toll Brothers, Inc.	3	13
Household Products — 0.5%		702

SCHEDULE OF PORTFOLIO INVESTMENTS

AS OF MARCH 31, 2022 (Unaudited) (continued)

ments	Shares (000)	Value (\$
Insurance — 1.0%	2	
Arthur J Gallagher & Co.	2	
Progressive Corp. (The)	10	1
V		1
Interactive Media & Services — 7.2%	2	
Alphabet, Inc., Class A *	2	6
Alphabet, Inc., Class C *	1	2
Meta Platforms, Inc., Class A *	5	1
Snap, Inc., Class A *	26	
L. 4 4 0 D' 4 M 4 D . 4 4 . 00 /		10
Internet & Direct Marketing Retail — 4.8% Amazon.com, Inc. *	2	7
	2	7
IT Services — 4.0%	2	
Affirm Holdings, Inc. * (a)	3	
Automatic Data Processing, Inc.	1	
FleetCor Technologies, Inc. *	3	
Mastercard, Inc., Class A	11	4
Shopify, Inc., Class A (Canada) *	1	
		5
Life Sciences Tools & Services — 0.5%		
Thermo Fisher Scientific, Inc.	1	
Machinery — 3.0%		
Deere & Co.	8	3
Dover Corp.	2	
Ingersoll Rand, Inc.	8	
Otis Worldwide Corp.	2	
Stanley Black & Decker, Inc.	3	
		4
Media — 0.4%		
Charter Communications, Inc., Class A *	1	
Comcast Corp., Class A	4	
Multi-Utilities — 0.3%		
Ameren Corp.	3	
CenterPoint Energy, Inc.	6	
Oil, Gas & Consumable Fuels — 2.5%		
Chevron Corp.	4	
ConocoPhillips	7	
Diamondback Energy, Inc.	3	
Pioneer Natural Resources Co.	8	2
		3
Personal Products — 0.2%		
Estee Lauder Cos., Inc. (The), Class A	1	
Pharmaceuticals — 3.2%		
Bristol-Myers Squibb Co.	37	2
Eli Lilly & Co.	5	1
Johnson & Johnson	2	
Merck & Co., Inc.	1	

Duefossional Caurioss 0.00/		
Professional Services — 0.9% Booz Allen Hamilton Holding Corp.	1	89
Leidos Holdings, Inc.	11	1,166
Leidos Holdings, inc.	11	1,255
Road & Rail — 2.6%		1,233
	0	222
Lyft, Inc., Class A *	9	332
Norfolk Southern Corp.	9	2,656
Uber Technologies, Inc. *	22	774
Union Pacific Corp.	— (b)	126
		3,888
Semiconductors & Semiconductor Equipment — 7.2%	22	2.560
Advanced Micro Devices, Inc. *	23	2,568
Analog Devices, Inc.	13	2,227
Lam Research Corp.	1	307
NVIDIA Corp.	3	782
NXP Semiconductors NV (China)	22	4,088
Teradyne, Inc.	1	170
Texas Instruments, Inc.	2	454
		10,596
Software — 8.9%		
Ceridian HCM Holding, Inc. *	7	497
Coupa Software, Inc. *	2	233
DocuSign, Inc. *	1	154
Intuit, Inc.	1	350
Microsoft Corp.	37	11,384
Workday, Inc., Class A *	1	296
		12,914
Specialty Retail — 3.0%		
Best Buy Co., Inc.	— (b)	23
Burlington Stores, Inc. *	1	244
Lowe's Cos., Inc.	10	1,988
O'Reilly Automotive, Inc. *	2	1,572
Ross Stores, Inc.	6	573
		4,400
Technology Hardware, Storage & Peripherals — 5.5%		
Apple, Inc.	45	7,912
Seagate Technology Holdings plc	3	225
		8,137
Textiles, Apparel & Luxury Goods — 1.1%		
NIKE, Inc., Class B	12	1,596
Wireless Telecommunication Services — 0.2%		
T-Mobile US, Inc. *	2	313
OTAL COMMON STOCKS		
Cost \$79,501)		143,114
20st \$77,5V1)		143,114
IODT TEDM INVESTMENTS 1 40/		
HORT-TERM INVESTMENTS — 1.4%		
IPMorgan LLS Government Manay Market Fund Class Institutional Shares (0.22% (a) (d)		
JPMorgan U.S. Government Money Market Fund Class Institutional Shares, 0.22% (c) (d)	1 052	1 052
(Cost \$1,853)	1,853	1,853

SCHEDULE OF PORTFOLIO INVESTMENTS

AS OF MARCH 31, 2022 (Unaudited) (continued)

Investments	Shares (000)	Value (\$000)
INVESTMENT OF CASH COLLATERAL FROM SECURITIES LOANED — 0.1%		
JPMorgan U.S. Government Money Market Fund Class IM Shares, 0.26% (c) (d)		
(Cost \$165)	165	165
TOTAL SHORT-TERM INVESTMENTS		
(Cost \$2,018)		2,018
Total Investments — 98.9%		<u> </u>
(Cost \$81,519)		145,132
Other Assets Less Liabilities — 1.1%		1,623
Net Assets — 100.0%		146,755

Percentages indicated are based on net assets.

- (a) The security or a portion of this security is on loan at March 31, 2022. The total value of securities on loan at March 31, 2022 is \$158.
- (b) Amount rounds to less than one thousand.
- (c) Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan Investment Management Inc.
- (d) The rate shown is the current yield as of March 31, 2022.
- * Non-income producing security.

Futures contracts outstanding as of March 31, 2022 (amounts in thousands, except number of contracts):

Description Long Contracts	Number of Contracts	Expiration Date	Trading Currency	Notional Amount (\$)	Value and Unrealized Appreciation (Depreciation) (\$)
S&P 500 E-Mini Index	12	06/2022	USD	2,719	28

Abbreviations

USD United States Dollar

SCHEDULE OF PORTFOLIO INVESTMENTS

AS OF MARCH 31, 2022 (Unaudited) (continued) (Dollar values in thousands)

A. Valuation of Investments — Investments are valued in accordance with U.S. generally accepted accounting principles ("GAAP") and the Portfolio's valuation policies set forth by, and under the supervision and responsibility of, the Board of Trustees of the Trust (the "Board"), which established the following approach to valuation, as described more fully below: (i) investments for which market quotations are readily available shall be valued at their market value and (ii) all other investments for which market quotations are not readily available shall be valued at their fair value as determined in good faith by the Board.

J.P. Morgan Investment Management Inc. (the "Administrator") has established the J.P. Morgan Asset Management Americas Valuation Committee ("AVC") to assist the Board with the oversight and monitoring of the valuation of the Portfolio's investments. The Administrator implements the valuation policies of the Portfolio's investments, as directed by the Board. The AVC oversees and carries out the policies for the valuation of investments held in the Portfolio. This includes monitoring the appropriateness of fair values based on results of ongoing valuation oversight including, but not limited, to consideration of macro or security specific events, market events, and pricing vendor and broker due diligence. The Administrator is responsible for discussing and assessing the potential impacts to the fair values on an ongoing basis, and, at least on a quarterly basis, with the AVC and the Board.

Equities and other exchange-traded instruments are valued at the last sale price or official market closing price on the primary exchange on which the instrument is traded before the net asset values ("NAV") of the Portfolio are calculated on a valuation date.

Investments in open-end investment companies ("Underlying Funds") are valued at each Underlying Fund's NAV per share as of the report date.

Futures contracts are generally valued on the basis of available market quotations.

Valuations reflected in this report are as of the report date. As a result, changes in valuation due to market events and/or issuer-related events after the report date and prior to issuance of the report are not reflected herein.

The various inputs that are used in determining the valuation of the Portfolio's investments are summarized into the three broad levels listed below.

- Level 1 Unadjusted inputs using quoted prices in active markets for identical investments.
- Level 2 Other significant observable inputs including, but not limited to, quoted prices for similar investments, inputs other than quoted prices that are observable for investments (such as interest rates, prepayment speeds, credit risk, etc.) or other market corroborated inputs.
- Level 3 Significant inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Portfolio's assumptions in determining the fair value of investments).

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input, both individually and in the aggregate, that is significant to the fair value measurement. The inputs or methodology used for valuing instruments are not necessarily an indication of the risk associated with investing in those instruments.

The following table represents each valuation input as presented on the Schedule of Portfolio Investments ("SOI"):

	Leve Quoted	prices	Other sign	Level 2 nificant observable inputs	Significar	evel 3 at unobservable inputs		otal
Total Investments in Securities (a)	\$ 143	5,132	\$	<u> </u>	\$	<u> </u>	\$145,132	
Appreciation in Other Financial Instruments								
Futures Contracts (a)	\$	28	\$	<u> </u>	\$	<u> </u>	\$	28

- (a) Please refer to the SOI for specifics of portfolio holdings.
- B. Investment Transactions with Affiliates The Portfolio invested in Underlying Funds, which are advised by the Adviser. An issuer

which is under common control with the Portfolio may be considered an affiliate. The Portfolio assumes the issuers listed in the table below to be affiliated issuers. Underlying Funds' distributions may be reinvested into such Underlying Funds. Reinvestment amounts are included in the purchases at cost amounts in the table below.

							I	For the pe	riod ei	ided March	31, 2	2022				
Security Description	Dece	nlue at mber 31, 2021		rchases t Cost		oceeds m Sales		Realized n (Loss)	Un App	hange in prealized preciation/ preciation)	Ma	alue at arch 31, 2022	Shares at March 31, 2022	Dividend Income		al Gain
JPMorgan U.S. Government Money Market Fund Class IM Shares, 0.26% (a) (b)	\$	409	<u>a</u> \$	1,730	<u>110</u>		\$	<u> </u>	<u>(Def</u>	<u>—</u>	\$	165	165	\$ —	_	\$
JPMorgan U.S. Government Money Market Fund Class Institutional Shares, 0.22% (a) (b)		1,333		6,546		6,026						1,853	1,853		(-)	
Total	\$	1,742	\$	8,276	\$	8,000	\$		\$	_	\$	2,018		s —	(c)	\$

- (a) Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan Investment Management Inc.
- (b) The rate shown is the current yield as of March 31, 2022.
- (c) Amount rounds to less than one thousand.